These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20503830)

  • 1. Treatment of patients with coronary artery disease with biodegradable polymer based paclitaxel-eluting Infinnium coronary stent system: results of 1-year clinical follow-up a single center experience.
    Vedat A; Selcuk G; Refik E; Onur E; Murat C; Burak CA; Murat G; Cemsid D
    Indian Heart J; 2009; 61(3):254-7. PubMed ID: 20503830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of left main coronary trifurcation lesions with the paclitaxel drug-eluting stent: mid-term outcomes from a tertiary medical center.
    Shammas NW; Shammas GA; Jerin M; Parikh A; Coin K; Dippel E; Sharis P; Robken J
    J Invasive Cardiol; 2009 Jul; 21(7):321-5. PubMed ID: 19571341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry.
    Karjalainen PP; Ylitalo A; Airaksinen JK; Nammas W
    J Interv Cardiol; 2011 Feb; 24(1):1-8. PubMed ID: 21039884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side balloon stenting of the left main bifurcation: a three-year angiographic follow-up.
    Latif F; Heldman AW; Hennebry TA
    J Interv Cardiol; 2009 Dec; 22(6):547-9. PubMed ID: 19735474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.
    Yarkoni A; Brodsky A; Sabapathy R; Pershad A
    Indian Heart J; 2008; 60(3):195-9. PubMed ID: 19240306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year clinical outcome after treatment of bare-metal stent in-stent restenosis with the paclitaxel-eluting stent in an unselected cohort.
    Beijk MA; Claessen BE; Koch KT; Henriques JP; Baan J; Vis MM; Meesterman M; Tijssen JG; Piek JJ; de Winter RJ
    Int J Cardiol; 2010 Dec; 145(3):608-9. PubMed ID: 20850881
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
    Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
    EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year outcomes of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: are they equally good (or bad)?
    Cutlip DE
    Circulation; 2011 Jun; 123(24):2779-81. PubMed ID: 21646497
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
    Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
    Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive plaque modification with rotational atherectomy and/or cutting balloon before drug-eluting stent implantation for the treatment of calcified coronary lesions.
    Vaquerizo B; Serra A; Miranda F; Triano JL; Sierra G; Delgado G; Puentes A; Mojal S; Brugera J
    J Interv Cardiol; 2010 Jun; 23(3):240-8. PubMed ID: 20636844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Chu WW; Kuchulakanti PK; Torguson R; Wang B; Clavijo LC; Suddath WO; Pichard AD; Satler LF; Kent KM; Waksman R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):62-6. PubMed ID: 16755592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
    Bavry AA; Kumbhani DJ; Helton TJ; Bhatt DL
    J Am Coll Cardiol; 2005 Mar; 45(6):941-6. PubMed ID: 15766833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
    Grube E; Dawkins KD; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Buellesfeld L; Koglin J; Russell ME
    Eur Heart J; 2007 Nov; 28(21):2578-82. PubMed ID: 17938126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-related outcomes after drug-eluting stent: should we "never mind" or "mind" the gap?
    Mehran R; Kini AS
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1260-1. PubMed ID: 21232719
    [No Abstract]   [Full Text] [Related]  

  • 19. One-year follow-up of nonrandomized comparison between coronary artery bypass grafting surgery and drug-eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >or=75 years).
    Ghenim R; Roncalli J; Tidjane AM; Bongard V; Ziani A; Boudou N; Dumonteil N; Marcheix B; Léobon B; Carrié D
    J Interv Cardiol; 2009 Dec; 22(6):520-6. PubMed ID: 19735473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT).
    Meliga E; Garcia-Garcia HM; Valgimigli M; Chieffo A; Biondi-Zoccai G; Maree AO; Gonzalo N; Cook S; Marra S; Moretti C; De Servi S; Palacios IF; Windecker S; van Domburg R; Colombo A; Sheiban I; Serruys PW
    Int J Cardiol; 2009 Sep; 137(1):16-21. PubMed ID: 18687481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.